Flag of the European Union EU Clinical Trials Register Help

Clinical trials for "prostate cancer" OR "breast cancer"

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    596 result(s) found for: "prostate cancer" OR "breast cancer". Displaying page 5 of 30.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-011079-57 Sponsor Protocol Number: BICG26UMCG-NIRF Start Date*: 2009-05-28
    Sponsor Name:University Medical Center Groningen
    Full Title: Evaluation of Indocyanine Green (ICG) enhanced Near-InfraRed Fluorescence (NIRF) Imaging for Intra-Operative Sentinel Lymph Node (SLN) detection in Breast Surgery.
    Medical condition: Women above the age of 21 with core biopsy or cytology proven breast cancer stage I and II, eligible for lumpectomy and sentinel lymph node procedure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006194 Breast cancer NOS stage I LLT
    9.1 10006195 Breast cancer NOS stage II LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001916-18 Sponsor Protocol Number: 20080331 Start Date*: 2008-11-05
    Sponsor Name:AZIENDA OSPEDALIERA ORDINE MAURIZIANO
    Full Title: A phase II, randomized trial with single agent trastuzumab or lapatinib in women with metastatic breast cancer iperexpressing HER2
    Medical condition: women with metastatic breast cancer iperexpressing HER2
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065430 LLT
    9.1 10055113 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006236-22 Sponsor Protocol Number: MET/TEST1106 Start Date*: 2007-01-31
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA O.I.R.M. - S. ANNA
    Full Title: Use of Metformin to reduce serum level of Testosterone and improve the metabolic picture in women treated for breast cancer
    Medical condition: Menopausal women on treatment for BC, with higher risk of recurrence due to augmented level of T
    Disease: Version SOC Term Classification Code Term Level
    6.1 10006187 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004836-76 Sponsor Protocol Number: Suprefact1 Start Date*: 2012-01-25
    Sponsor Name:Urologkliniken USÖ
    Full Title: Suprefact1 Can Suprefact be administrated every forth month with good castration effect.
    Medical condition: Prostate cancer that need hormone treatment by LHRH-agoniste.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004513-27 Sponsor Protocol Number: MedOPP127 Start Date*: 2017-09-04
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes
    Medical condition: Hormone receptor-(HR)positive/HER2-negative metastatic breast cancer (MBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020826 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002289-35 Sponsor Protocol Number: SGNLVA-002 Start Date*: 2018-04-02
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast C...
    Medical condition: Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-004091-21 Sponsor Protocol Number: UCL/16/0587 Start Date*: 2017-08-23
    Sponsor Name:University College London
    Full Title: Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature
    Medical condition: Metastatic castrate resistant prostate cancer (prostate adenocarcinoma)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001198 Adenocarcinoma of the prostate metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-020681-16 Sponsor Protocol Number: LO-10-01 Start Date*: 2010-10-12
    Sponsor Name:Lunamed Operations AG
    Full Title: A PILOT STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND EFFICACY OF A DAILY DOSE OF 500MG. LU901 (4PHENYL-BUTYRATE, CONTROLLED RELEASE TABLETS) IN ADDITION TO STANDARD HORMONAL TREATMENT IN PATIE...
    Medical condition: Patients suffering from prostate carcinoma with progression under first line hormonal treatment. Patients entering the study should have a life expectancy prognosis of at least 6 months.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10007453 Carcinoma of the prostate metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001146-34 Sponsor Protocol Number: 1301 Start Date*: 2015-02-20
    Sponsor Name:Centre Oscar Lambret
    Full Title: Impact of a treatment with zoledronic acid on bone mineral density in patients with metastatic castration-resistant prostate cancer, chemo-naïve and receiving abiraterone acetate
    Medical condition: Metastatic castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-003007-19 Sponsor Protocol Number: MK-7339-002 Start Date*: 2018-11-29
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
    Medical condition: Homologous recombination repair mutation (HRRm) or Homologous recombination deficiency (HRD) positive cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) IE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001587-19 Sponsor Protocol Number: UHSM0315 Start Date*: 2015-07-15
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: A pilot prevention study of the effects of the anti-progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk
    Medical condition: We seek to investigate the breast cancer risk reducing properties of ulipristal acetate
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10004746 Biopsy breast normal PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10022891 - Investigations 10071224 Breast scan PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-001998-10 Sponsor Protocol Number: Create-01 Start Date*: 2011-10-17
    Sponsor Name:Department of Oncology University Hospital Uppsala
    Full Title: An International Randomized Phase II Study Comparing Early Electrochemotherapy to Delayed or No Electrochemotherapy in Patients with Cutaneous Breast Cancer Metastases
    Medical condition: Breast cancer that has spread to the skin
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000120-14 Sponsor Protocol Number: ASL605LIOM01 MYTA Start Date*: 2006-10-11
    Sponsor Name:AZIENDA USL 6 LIVORNO ZONA LIVORNESE
    Full Title: Study of the association of docetaxel and liposomial doxorubicin Myocet in metastatic breast cancer phase II clinical trial
    Medical condition: Patiens with metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018795-24 Sponsor Protocol Number: APREC S-2010-01 Start Date*: 2010-06-01
    Sponsor Name:Alliance pour la recherche en cancérologie
    Full Title: Evaluation of the effect of pasireotide LAR administration in the lymphocele prevention after axillary node dissection for breast cancer
    Medical condition: BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003734-32 Sponsor Protocol Number: BXCL701-201 Start Date*: 2019-07-02
    Sponsor Name:BioXcel Therapeutics, Inc
    Full Title: A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab ...
    Medical condition: Small Cell Neuroendocrine Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-004450-24 Sponsor Protocol Number: PHIX-IT Start Date*: 2019-08-01
    Sponsor Name:Tergooi Hospital, dep of internal medicine
    Full Title: A pharmacokinetic study of edoxaban in patients with breast cancer using the P-glycoprotein inhibitor tamoxifen
    Medical condition: If there are increased plasma levels of edoxaban when used concomitantly with the P-glycoproteïne inhibitor tamoxifen for the treatment of venous thromboembolism in patients with breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003212-39 Sponsor Protocol Number: LPM-008 Start Date*: 2019-12-17
    Sponsor Name:Lightpoint Medical Ltd
    Full Title: Evaluation of the LightPath Imaging System and the PET tracer 68Ga-RM2 in wide local excision (WLE) for breast cancer
    Medical condition: Wide local excision (WLE) for breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006290 Breast and nipple neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003106-16 Sponsor Protocol Number: B2 Start Date*: 2016-08-03
    Sponsor Name:Antonis Valachis
    Full Title: Immunogenicity of influenza vaccination among breast cancer patients treated with trastuzumab in adjuvant setting
    Medical condition: Efficacy of vaccination against influenza in patients with breast cancer treated with Trastuzumab as adjuvant therapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-009921-28 Sponsor Protocol Number: PLOTINA Start Date*: 2010-05-15
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: The Effect of Metformin, an insulin-sensitizing drug, on Breast Cancer Primary Prevention: The Plotina Breast Cancer Prevention Randomized, Placebo Controlled Trial
    Medical condition: Breast cancer chemoprevention
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002616-16 Sponsor Protocol Number: NL49061.031.14 Start Date*: 2014-07-10
    Sponsor Name:NKI-AVL
    Full Title: Pilot for high-resolution SPECT imaging of breast cancer lumpectomy specimens for 3D identification and quantification of resection margins
    Medical condition: Patients with breast cancer, IDC (n=3) and DCIS (n=3) scheduled for a lumpectomy.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 05 09:58:47 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA